Advertisement

Topics

FDA Approves Pfizer’s Fragmin, as the First Anticoagulant for Pediatric Patients to Treat Potentially Life-Threatening Blood Clots

09:53 EDT 17 May 2019 | Speciality Pharma Journal

The U.S. Food and Drug Administration today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older. VTE can include deep vein thrombosis (blood clot in the deep veins of the leg) and pulmonary embolism (blood clot in the …

Original Article: FDA Approves Pfizer’s Fragmin, as the First Anticoagulant for Pediatric Patients to Treat Potentially Life-Threatening Blood Clots

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Pfizer’s Fragmin, as the First Anticoagulant for Pediatric Patients to Treat Potentially Life-Threatening Blood Clots"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...